Thomas Vanassche1, Christelle Orlando2, Kristel Vandenbosch3, Alain Gadisseur4, Cédric Hermans5, Kristin Jochmans2, Jean-Marc Minon6, Serge Motte7, Harlinde Peperstraete8, Pierre Péters3, Muriel Sprynger9, Patrizio Lancellotti9, Isabelle Dehaene10, Patrick Emonts11, Christophe Vandenbriele1, Peter Verhamme1, Cécile Oury12. 1. Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium. 2. Department of Haematology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel, Brussels, Belgium. 3. Department of Laboratory Haematology, CHU University Hospital of Liège, Liège, Belgium. 4. Department of Haematology, Antwerp University Hospital, Antwerp, Belgium. 5. Department of Haematology, Cliniques Universitaires St-Luc, Brussels, Belgium. 6. Department of Laboratory Medicine, Thrombosis-haemostasis and Transfusion Unit, CHR Citadelle, Liège, Belgium. 7. Department of Vascular Diseases, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium. 8. Department of Cardiac Intensive Care, Ghent University Hospital, Ghent, Belgium. 9. Department of Cardiology, CHU University Hospital of Liège, Liège, Belgium. 10. Vlaamse Vereniging voor Obstetrie en Gynaecologie, Universitair Ziekenhuis Gent, Ghent, Belgium. 11. Groupement des Gynécologues Obstétriciens de Langue Française de Belgique, CHU University Hospital of Liège. 12. Laboratory of Cardiology, GIGA Institute, University of Liège, Liège, Belgium.
Abstract
OBJECTIVES: COVID-19 predisposes patients to thrombotic disease. The aim of this guidance document is to provide Belgian health-care workers with recommendations on anticoagulation management in COVID-19 positive patients. METHODS: These recommendations were based on current knowledge and a limited level of evidence. RESULTS: We formulated recommendations for the prophylaxis and treatment of COVID-related venous thromboembolism in ambulatory and hospitalised patients, as well as recommendations for the use of antithrombotic drugs in patients with prior indication for anticoagulation who develop COVID-19. CONCLUSIONS: These recommendations represent an easy-to-use practical guidance that can be implemented in every Belgian hospital and be used by primary care physicians and gynaecologists. Of note, they are likely to evolve with increased knowledge of the disease and availability of data from ongoing clinical trials.
OBJECTIVES: COVID-19 predisposes patients to thrombotic disease. The aim of this guidance document is to provide Belgian health-care workers with recommendations on anticoagulation management in COVID-19 positive patients. METHODS: These recommendations were based on current knowledge and a limited level of evidence. RESULTS: We formulated recommendations for the prophylaxis and treatment of COVID-related venous thromboembolism in ambulatory and hospitalised patients, as well as recommendations for the use of antithrombotic drugs in patients with prior indication for anticoagulation who develop COVID-19. CONCLUSIONS: These recommendations represent an easy-to-use practical guidance that can be implemented in every Belgian hospital and be used by primary care physicians and gynaecologists. Of note, they are likely to evolve with increased knowledge of the disease and availability of data from ongoing clinical trials.
Entities:
Keywords:
COVID-19; Practice guideline; primary health care